... Skip to content
World IP Day 2026 — Recognized Innovator

Dr. Navnit Shah

  • President & CSO
  • Kashiv BioSciences LLC

Hero statement: Recognized for decades of scientific leadership in pharmaceutical R&D. Navnit is an AAPS Fellow, Thomas Alva Edison Patent Award winner, and former Roche distinguished scientist whose work on amorphous solid dispersions and drug delivery now guides Kashiv BioSciences’ biosimilar and complex peptide development pipeline.

Certificate of Recognition

Top IP Innovator — Biosimilars & Drug Delivery · 2026

Kashiv Patents (last 5 years)
0
First Filing
2011
USPTO Art Unit Focus
1641 / 1678 / 1777
Role
President & CSO
Presented by InspireIP

World IP Day Recognition Series · 2026

Kashiv BioSciences patents, last 5 years
0
Filed in 2024 alone
0
Recognition category
0 Biotech & Organic
The Recognition

Advancing complex medicines through formulation and biopharma R&D

On World IP Day 2026, InspireIP recognizes Dr. Navnit Shah, President and Chief Scientific Officer of Kashiv BioSciences, for his scientific leadership at the company building one of the most active biosimilar and complex peptide development programs in the United States.

The recognition is based on Kashiv’s patent activity and Dr. Shah’s broader inventor footprint. At Kashiv, that work is reflected in a 30+-patent portfolio over the last five years, protecting the company’s biosimilar, 505(b)(2), and complex peptide platforms.

Dr. Shah holds a PhD in Pharmaceutics from St. John’s University. Before Kashiv, he spent decades at Hoffmann-La Roche, where he served as a distinguished scientist and led oral dosage form development.

His work has focused heavily on drug delivery and amorphous solid dispersions. At Kashiv, that experience now supports the development of complex medicines designed for regulated global markets.

Biosimilars
Complex Peptides
Drug Delivery Systems
Amorphous Solid Dispersions
505(b)(2) Pathway
Specialty Biopharmaceuticals
Patent Footprint

A portfolio shaped around expanding access to complex medicines

2011–2018

Kashiv BioSciences is established as a fully integrated biopharmaceutical company. Early filings cover drug delivery technologies, formulation methods, and specialty biopharmaceutical platforms.

2019–2021

Kashiv continues building its biosimilar and complex peptide pipeline. The company expands its R&D and manufacturing footprint across the United States and India.

2022–2023

Patent activity grows across biosimilars, biologics, and complex peptide programs. The company advances development work across multiple therapeutic areas.

2024–2025

Kashiv records its most active filing year, with 15 filings in 2024. The company also expands its complex peptide and biosimilar work through financing, manufacturing growth, and licensing activity.

Biosimilars & Drug Delivery

A small-entity company filing alongside global biopharma

Kashiv BioSciences is classified by the USPTO as a Small Entity, yet its five-year filing volume of 30 patents reflects a vertically integrated biopharmaceutical company with R&D, manufacturing, and IP capabilities spanning two continents. The portfolio is concentrated in the biotech, organic chemistry, and chemical materials art units that protect biosimilar formulations, complex peptide compositions, and specialty drug delivery technologies.

Patents, last 5 years
Peak year
USPTO entity status
Small Entity
Art unit focus
1641 / 1678 / 1777
"Leading an innovation program is harder than inventing on your own. It means choosing what to file, who to credit, and where to invest, over and over, for years. The leaders we recognize on World IP Day have done that consistently, and built something that compounds."

Sam Zellner

Founder, InspireIP · Inventor · Innovation Leader

About Kashiv BioSciences

Built across the US and India, expanding access to complex medicines

Established in 2011 and headquartered in Bridgewater, New Jersey, Kashiv BioSciences is a fully integrated biopharmaceutical company with operations across the United States and India.

The company develops biosimilars, 505(b)(2) products, and generic complex peptides. The company’s pipeline spans therapeutic areas including CNS, endocrinology, oncology, and orphan diseases.

Kashiv operates across R&D, manufacturing, and fill-finish capabilities. Its work is focused on expanding access to complex medicines through integrated development and manufacturing.

In 2026, Kashiv agreed to be acquired by Amneal Pharmaceuticals and also signed an exclusive licensing agreement with Intas Pharmaceuticals for complex peptide products in Europe, the UK, and India.

IP Day 2027

Know an IP innovator who deserves recognition?

Each year we recognize the inventors and IP leaders behind the portfolios that protect what their companies create. That includes founder-inventors whose contributions often go unmarked. Nominate someone for next year’s list.

Subscribe to Trust Center Updates

Subscribe to get notifications about important update to InspireIP's compliance journey.
By signing up for email notifications you agree to the privacy policy.

InspireIP has restricted access for 'System Acquisition and Development Lifecycle Policy'. We need your work email to validate OR request your access to this item.